Drugs / rostaporfin
rostaporfin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00002167 | — | HIV infectious disease, Kaposi's sarcoma | Clinical Solutions | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00157976 | Sep 2005 → ? | macular degeneration | Miravant Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rostaporfin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00157976 ↗ |
| Known as | Photrex | “Photrex (rostaporfin)” NCT00157976 ↗ |
| Known as | SnET2 | “To determine the objective tumor response and remission rate of AIDS-related Kaposi's sarcomas (KS) following a single dose of tin ethyl etiopurpurin (SnET2) followed by...” NCT00002167 ↗ |
| Known as | Tin ethyl etiopurpurin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002167 ↗ |